The U.S. Solicitor General filed a brief urging the Supreme Court to reverse an appeals‑court decision that had revived Amarin’s lawsuit against generic maker Hikma over skinny‑labeling for Vascepa. DOJ lawyers argued the Delaware appeals ruling undermines Congress’s statutory pathway for generics and would expand inducement liability absent specific allegations that the defendant encouraged off‑label use beyond selling the product. The High Court accepted Hikma’s petition. The case probes core questions about the legal safe harbor for generics that market with truncated labels and the extent to which promotional statements can trigger patent inducement claims. Drugmakers and industry groups are watching closely given implications for generic launch strategies and litigation exposure. Regulatory/legal note: “Skinny labeling” allows generics to seek approval for a subset of indications; the Supreme Court decision will affect how patent holders and generic entrants litigate promotional conduct tied to label scope.